In order to develop drugs to treat or prevent human disease a significant amount of complex scientific research needs to be done. Nexus BioQuest is a pre-clinical contract research organisation that collaborates with Biotechnology and Pharmaceutical companies in order to help accelerate their pre-clinical immunology research programmes. At our core we have: • Expertise- Deep immunology experience and knowledge in order to solve complex research problems. • Tempo- Agile and quickly expandable capability focused on reducing bureaucracy and burden so that collaborative science can thrive. • Collaboration- Be open and mutually trusting to maximise the impact of research and step away from a transactional approach. Our science will provide a comprehensive suite of solutions which will model the immune response depending on the research question being asked. These will form a pre-clinical package of assays including: • Relevant target expression. • Mode of action. • Efficacy. • Biomarkers. • Predictive immuno-toxicity. This will allow us to support our partners at multiple steps within the preclinical drug development process. All of our work is built on our deep understanding of the immune response, allowing us to provide relevant, customisable, cutting-edge assays, to advance our partners' drug development programs.
NGT BioPharma Consultants is an innovative drug development consulting firm and transactional business development partner, providing strategic advice, operational services, transactional support, and tailored solutions across discovery, preclinical and clinical development, registration, commercialization, and product life-cycle management.
The Nikon BioImaging Lab (NBIL) is a Contract Research Organization (CRO) that provides microscope-based imaging and analysis services to the biotech, pharma, and larger research communities, offering contract research services from the company that knows imaging.
No data available
No data available
Nuclera is a US and UK-based biotechnology company driven by the mission to better human health by making proteins accessible. Nuclera is enabling life science researchers to obtain active proteins from DNA in 48 hours through its benchtop eProtein DiscoveryTM platform.
Website: https://www.nuclera.com
Contact: [email protected]
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Website: https://www.nuclera.com
Contact: [email protected]
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
No data available
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes.
No data available
OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.?